281 related articles for article (PubMed ID: 25284480)
1. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.
Cheung LW; Yu S; Zhang D; Li J; Ng PK; Panupinthu N; Mitra S; Ju Z; Yu Q; Liang H; Hawke DH; Lu Y; Broaddus RR; Mills GB
Cancer Cell; 2014 Oct; 26(4):479-94. PubMed ID: 25284480
[TBL] [Abstract][Full Text] [Related]
2. Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.
Cheung LW; Mills GB
Pharmacogenomics; 2016 Feb; 17(3):297-307. PubMed ID: 26807692
[TBL] [Abstract][Full Text] [Related]
3. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract][Full Text] [Related]
4. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Turturro SB; Najor MS; Yung T; Portt L; Malarkey CS; Abukhdeir AM; Cobleigh MA
Breast Cancer Res Treat; 2019 Sep; 177(2):325-333. PubMed ID: 31209687
[TBL] [Abstract][Full Text] [Related]
5. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
6. Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Ross RL; Burns JE; Taylor CF; Mellor P; Anderson DH; Knowles MA
PLoS One; 2013; 8(12):e84411. PubMed ID: 24367658
[TBL] [Abstract][Full Text] [Related]
7. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
8. The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer.
Vallejo-Díaz J; Chagoyen M; Olazabal-Morán M; González-García A; Carrera AC
Trends Cancer; 2019 Apr; 5(4):233-244. PubMed ID: 30961830
[TBL] [Abstract][Full Text] [Related]
9. p85α neomorphic mutants: splitting away from the canonical path.
Cheung LW; Mills GB
Mol Cell Oncol; 2015; 2(4):e983388. PubMed ID: 27308516
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs. insulin-like growth factor-I in myogenic cells.
Halevy O; Cantley LC
Exp Cell Res; 2004 Jul; 297(1):224-34. PubMed ID: 15194438
[TBL] [Abstract][Full Text] [Related]
11. A human immunodeficiency caused by mutations in the PIK3R1 gene.
Deau MC; Heurtier L; Frange P; Suarez F; Bole-Feysot C; Nitschke P; Cavazzana M; Picard C; Durandy A; Fischer A; Kracker S
J Clin Invest; 2014 Sep; 124(9):3923-8. PubMed ID: 25133428
[TBL] [Abstract][Full Text] [Related]
12. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Huang-Doran I; Tomlinson P; Payne F; Gast A; Sleigh A; Bottomley W; Harris J; Daly A; Rocha N; Rudge S; Clark J; Kwok A; Romeo S; McCann E; Müksch B; Dattani M; Zucchini S; Wakelam M; Foukas LC; Savage DB; Murphy R; O'Rahilly S; Barroso I; Semple RK
JCI Insight; 2016 Oct; 1(17):e88766. PubMed ID: 27766312
[TBL] [Abstract][Full Text] [Related]
15. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.
Terauchi Y; Tsuji Y; Satoh S; Minoura H; Murakami K; Okuno A; Inukai K; Asano T; Kaburagi Y; Ueki K; Nakajima H; Hanafusa T; Matsuzawa Y; Sekihara H; Yin Y; Barrett JC; Oda H; Ishikawa T; Akanuma Y; Komuro I; Suzuki M; Yamamura K; Kodama T; Suzuki H; Yamamura K; Kodama T; Suzuki H; Koyasu S; Aizawa S; Tobe K; Fukui Y; Yazaki Y; Kadowaki T
Nat Genet; 1999 Feb; 21(2):230-5. PubMed ID: 9988280
[TBL] [Abstract][Full Text] [Related]
16. The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer.
Chakraborty G; Nandakumar S; Hirani R; Nguyen B; Stopsack KH; Kreitzer C; Rajanala SH; Ghale R; Mazzu YZ; Pillarsetty NVK; Lee GM; Scher HI; Morris MJ; Traina T; Razavi P; Abida W; Durack JC; Solomon SB; Vander Heiden MG; Mucci LA; Wibmer AG; Schultz N; Kantoff PW
Clin Cancer Res; 2022 Aug; 28(16):3603-3617. PubMed ID: 35670774
[TBL] [Abstract][Full Text] [Related]
17. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
Wee S; Jagani Z; Xiang KX; Loo A; Dorsch M; Yao YM; Sellers WR; Lengauer C; Stegmeier F
Cancer Res; 2009 May; 69(10):4286-93. PubMed ID: 19401449
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
19. PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Cizkova M; Vacher S; Meseure D; Trassard M; Susini A; Mlcuchova D; Callens C; Rouleau E; Spyratos F; Lidereau R; Bièche I
BMC Cancer; 2013 Nov; 13():545. PubMed ID: 24229379
[TBL] [Abstract][Full Text] [Related]
20. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
